Arca
Skip to content

B-cell acute lymphoblastic leukemia

Drug research and approvals for B-cell acute lymphoblastic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 215 studies of B-cell acute lymphoblastic leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, and FDA has 2 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 215
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 215 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 11; search them all in Canada trials
May 28, 2026Open label dose-escalation and dose expansion study to evaluate the safety, expansion, persistence and clinical activity of ucart22 {allogeneic engineered…UCART22 / CLLS52CELLECTIS S.A.Closed
Apr 15, 2026A phase 2/3, randomized, open-label, comparison study of mk-1045 versus blinatumomab in participants with relapsed or refractory cd 19+ b-cell acute…MK-1045Merck & Co. (MSD)Ongoing
Dec 23, 2025Phase II study of subcutaneous blinatumomab plus ponatinib for bcr-abl positive b-cell acute lymphoblastic leukemiaBLINCYTO / ICLUSIGTHE GOVERNORS OF THE UNIVERSITY OF ALBERTAPending
Nov 27, 2025A phase 3, open-label, randomized, controlled trial of subcutaneous versus intravenous blinatumomab in newly diagnosed adults with philadelphia chromosome…SUBCUTANEOUS (SC) BLINATUMOMAB / RITUXIMABAmgenPending
Sep 5, 2025A phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of administration of subcutaneous (sc) blinatumomab in pediatric participants with…BLINCYTOAmgenPending
Aug 14, 2025An international pilot study of chemotherapy and tyrosine kinase inhibitors with blinatumomab in patients with newly-diognosed philadelphia chromosome-positive…BLINCYTOCHILDRENS ONCOLOGY GROUPOngoing
Jun 10, 2022A phase 1/2 open-label study to investigate the safety, efficacy, and pharmacokinetics of administration of subcutaneous blinatumomab for the treatment of…BLINATUMOMAB (SC)AmgenOngoing
Feb 11, 2021A phase II pilot trial to estimate survuval after a non-total body irradiation (tbi) based conditioning regimen in patients diagnosed with b-acute…THIOTEPAPEDIATRIC TRANSPLANTATION AND CELLULAR THERAPY CONSORTIUMClosed
Feb 5, 2021A phase 2 study of blinatumomab (nsc# 765986, ind# 125462) in combination with nivolumab (nsc # 748726, ind# 125462), a checkpoint inhibitor of pd-1, in b-all…BLINCYTO / OPDIVOCHILDRENS ONCOLOGY GROUPOngoing
Apr 10, 2019A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-cd22 monoclonal antibody) to frontline therapy in young…INOTUZUMAB OZOGAMICIN / RITUXANCANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 6, 2024Besponsatreatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1…Wyeth Pharmaceuticals, LLCApproved
Aug 17, 2017inotuzumab ozogamicinTreatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)Wyeth Pharmaceuticals, LLCApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.